A Phase 2 Study of BGJ398 in Patients With Recurrent GBM

Summary

This is an open-label non-randomized, multicenter, phase II study of BGJ398 administered to adult patients with histologically confirmed GBM and/or other glioma subtypes with FGFR1-TACC1, FGFR3-TACC3 fusion and/or activating mutation in FGFR1, 2 or 3.

Timeline

Start

2013-12-09

Primary completion

2018-10-03

Completion

2018-10-03

Drugs

Indications